Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR T-cell therapies are forging a path towards improvi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2022.13.085 |